Literature DB >> 2254384

Long-term application of vindesine: toxicity and tolerance.

W Rhomberg1, H Eiter, E Soltesz, F Böhler.   

Abstract

This is a report on 14 patients receiving vindesine continuously for between 1 and 7 years. Total vindesine doses ranged from 86 mg to 454 mg and the longest treatment duration was 2564 days. Although there was no patient without a transient acute or subacute toxicity, no unequivocal signs of long-term toxicity have been observed so far. Greater caution must be given to the concomitant use of higher radiation doses and vindesine, since local reactions were more pronounced especially at the lung. The drug seems to be tolerated for longer periods without major or cumulative toxicity, which makes it suitable for use in the adjuvant setting, for instance, or within an antimetastatic approach.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2254384     DOI: 10.1007/bf01637089

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  6 in total

Review 1.  Effect of microtubule inhibitors on invasion and on related activities of tumor cells.

Authors:  M M Mareel; M De Mets
Journal:  Int Rev Cytol       Date:  1984

2.  Weight gain in patients receiving adjuvant chemotherapy for carcinoma of the breast.

Authors:  M O Huntington
Journal:  Cancer       Date:  1985-08-01       Impact factor: 6.860

3.  Weight gain in women with breast cancer receiving adjuvant chemotherapy.

Authors:  M K Knobf; J C Mullen; D Xistris; D A Moritz
Journal:  Oncol Nurs Forum       Date:  1983       Impact factor: 2.172

Review 4.  Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate).

Authors:  R W Dyke; R L Nelson
Journal:  Cancer Treat Rev       Date:  1977-06       Impact factor: 12.111

5.  Vindesine for recurrent and metastatic cancer of the uterine cervix: a phase II study.

Authors:  W U Rhomberg
Journal:  Cancer Treat Rep       Date:  1986-12

6.  Investigation of the in vivo anti-invasive and anti-metastatic effect of desacetyl vinblastine amide sulphate or vindesine.

Authors:  G Atassi; P Dumont; M Vandendris
Journal:  Invasion Metastasis       Date:  1982
  6 in total
  1 in total

1.  Combined vindesine and razoxane shows antimetastatic activity in advanced soft tissue sarcomas.

Authors:  Walter Rhomberg; Helmut Eiter; Franz Schmid; Christoph H Saely
Journal:  Clin Exp Metastasis       Date:  2007-10-12       Impact factor: 5.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.